In conclusion, our study showed that c-Myc could promote the development of pancreatic cancer, and c-Myc downregulation could synergistically enhance the antitumor activity of bufalin by downregulating the HIF-1α/SDF-1/CXCR4 pathway. This evidence concerns the gene CXCL12 and familial pancreatic carcinoma.